News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DBV Technologies and Centre d'Immunologie de Marseille-Luminy (CIML) Enter in a Collaboration Agreement


10/16/2012 10:17:50 AM

BAGNEUX, France--(BUSINESS WIRE)--Regulatory News: DBV Technologies (Paris:DBV) (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, announced today a partnership with Dr. Bernard Malissen who is working at the Centre d'Immunologie de Marseille-Luminy (CIML). His team is studying immune cells involved in allergic reactions (lymphocytes T and dendritic cells study). DBV Technologies and CIML have decided to collaborate to improve their knowledge of recruitment and mechanisms of actions involved in the epicutaneous treatment of allergies by the EPIT® (Epicutaneous Immunotherapy) method.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES